GO:0072526Ontology (GO BP)GO biological process · ~8 member genes
Q-omics provides the Pyridine-containing compound catabolic process (GO:0072526) pathway profile, scoring each patient from the combined activity of its roughly 8 member genes. Pathway activity is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, the pathway is differentially active in 8, with the highest sampling consensus in BLCA. Additionally, pathway RNA activity shows 34,745 significant cross-omics associations, again with the highest sampling consensus in STAD. Together, these results highlight UVM, BLCA, and STAD as cancer lineages where the pathway shows reproducible signals across outcome, tissue activity, and molecular association analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns. Pathway-against-pathway and pathway-against-mutation comparisons are not available for ontology entities.
Survival associations
This table summarizes Pyridine-containing compound catabolic process survival associations by molecular data type. RNA-level pathway activity shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each layer.
This table ranks reproducible pathway activity–survival associations across cancer types. High Pyridine-containing compound catabolic process activity shows favorable associations in LGG and UCS, but unfavorable associations in UVM, ACC, LUSC and DLBC. In the UVM Kaplan–Meier curve the high-activity group declines faster, consistent with the unfavorable association (log-rank p < 0.001). UVM ranks highest by sampling consensus for Pyridine-containing compound catabolic process.
This table summarizes Pyridine-containing compound catabolic process tumor–normal activity differences by data type. RNA-level activity shows significant tumor–normal differences in 8 cancer types, while mass-spec protein activity shows differences in 4. The strongest signals are in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal activity differences for the pathway. A positive fold-change indicates higher activity in tumor tissue. The pathway shows consistently lower tumor activity across BLCA, LUSC, KICH, BRCA, THCA and LIHC. In the BLCA box plot, normal samples show higher pathway activity than tumor samples (log2 FC = −0.084, t-test p = .015).
This table shows molecular features associated with Pyridine-containing compound catabolic process pathway activity in patient tissues and cancer cell lines. In patient samples, pathway activity is most strongly linked to RNA and protein features, with the largest associated set in STAD. In cancer cell lines, RNA-expression features and functional dependencies dominate, with the largest set in BONE.
